Johnson & Johnson is Acquiring Halda Therapeutics.

Johnson & Johnson Acquiring Halda Therapeutics

Johnson & Johnson (JNJ) has agreed to acquire the privately-held Halda Therapeutics company for a cash consideration of $3.05 billion. This acquisition allows the company to expand its cancer portfolio by focusing on solid tumors and prostate cancer. This deal, which is Johnson & Johnson's second-largest transaction of the year, follows the acquisition of Intra-Cellular Therapies for $14.6 billion.

This agreement reinforces Johnson & Johnson's strategy to invest in high-growth areas following the expiration of exclusivity for its top-selling immunology treatment Stelara. In recent years, the company has accelerated its activities in the pharmaceuticals and medical devices sectors; in 2024, it had acquired Shockwave Medical for $13.1 billion.

Halda Therapeutics's leading asset, HLD-0915, is in early to mid-stage development for prostate cancer and is part of a broader pipeline that includes treatment options for breast, lung, and other solid tumors. Analysts noted that this acquisition offers medium- and long-term growth potential for Johnson & Johnson's oncology segment.

Johnson & Johnson stated that Halda has the ability to bind cancer biomarkers to vital proteins through its RiPTAC technology, providing an effective mechanism by targeting these proteins in tumor cells while preserving healthy tissues. The company believes that this mechanism could be beneficial in the fight against cancers that do not respond to standard treatments.